EXPRESS ZERTIFIKAT - E.ON/LINDE/FRESENIUS Share Price

Certificat

DE000CS8S135

Market Closed - Deutsche Boerse AG 16:00:26 28/05/2024 BST
922.1 EUR +0.94% Intraday chart for EXPRESS ZERTIFIKAT - E.ON/LINDE/FRESENIUS
Current month+3.47%
1 month+5.36%
Date Price Change
28/05/24 922.1 +0.94%
27/05/24 913.5 +0.21%
24/05/24 911.6 +1.61%
23/05/24 897.2 +1.57%
22/05/24 883.3 +0.43%

Delayed Quote Deutsche Boerse AG

Last update May 28, 2024 at 04:00 pm

More quotes

Static data

Product typeOther Certificates
Buy / SellCALL
Underlying FRESENIUS SE & CO. KGAA
Issuer Credit Suisse
WKN CS8S13
ISINDE000CS8S135
Date issued 26/02/2020
Strike 30.79
Maturity 21/04/2026 (693 Days)
Parity 0.03 : 1
Emission price 1,000
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 1,014
Lowest since issue 476.1

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
Sector
-
More about the company

Ratings for Fresenius SE & Co. KGaA

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius SE & Co. KGaA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
29.23 EUR
Average target price
36.72 EUR
Spread / Average Target
+25.64%
Consensus